Variants of SARS-CoV-2 have emerged that are more transmissible than the original virus or
that exhibit some properties of immune escape, or both. The beta (B. 1.351) variant has …

Background The present study aimed to evaluate the persistent immunogenicity offered by a
third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) …

Background Understanding the duration of protection and risk of reinfection after natural
infection is crucial to planning COVID-19 vaccination for at-risk groups, including care home …

Since the emergence of the SARS-CoV-2 pandemic, various genetic variants have been
described. The B. 1.1. 7 variant, which emerged in England during December 2020, is …

Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare
workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects …

Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Background Residents of long-term care facilities (LTCFs) have been prioritised for COVID-
19 vaccination because of the high COVID-19 mortality in this population. Several countries …

Background Residents and staff in long-term care facilities have been prioritised for
vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness and …

Background SARS-CoV-2 infection represents a major challenge for long-term care facilities
(LTCFs) and many residents and staff are seropositive following persistent outbreaks. We …

Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …